knowledge -WSS

knowledge

author：knowledge 2025-09-06 05:03:09 - browse：8

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

WSS

As H5N1 spreads in cows, experts warn against drinking raw milk

Bill would stop addiction treatment from triggering child abuse inquiry

STAT series 'Denied by AI' wins major journalism prizes

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Sana to lay off nearly a third of staff, de

3 questions for the future of Biden's cancer moonshot

entertainment

knowledge

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Liquid biopsy for lung cancer is launched by Delfi

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Sports medicine is finally prioritizing gender equality

Ripples from Flovent's discontinuation is killing children with asthma

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Chemotherapy drug shortage eases slightly but still widespread

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

focus

Senate panel eyes new effort on drug shortages

Senate panel eyes new effort on drug shortages

Obesity drug from Roche shows promise in early study

CVS is willing to dump 10% of its Medicare Advantage members

Fertility clinic egg and embryo storage is a disaster

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

leisure time

focus

explore

leisure time